[Lung Cancer Advanced Treatment] New Benchmark in Neoadjuvant Immunotherapy: Toripalimab Demonstrates Significant Perioperative Benefit in the NEOTORCH Trial

For Stage III non-small cell lung cancer (NSCLC) patients, surgery alone often fails to achieve curative goals. A pivotal study presented at ASCO 2023 — the NEOTORCH trial — provides a new approach for this stage: preoperative use of toripalimab plus chemotherapy not only shrinks tumors effectively but also significantly improves long-term patient outcomes.

I. NEOTORCH Trial: Remarkable Pathological Response Data

This randomized, double-blind trial enrolled 404 resectable Stage III patients, evaluating "toripalimab + chemotherapy" versus "placebo + chemotherapy."

Key Clinical Endpoints:

• Event-Free Survival (EFS): The combination arm demonstrated powerful disease control (median EFS not yet reached), significantly superior to the placebo arm's 15.1 months.
• Major Pathological Response (MPR): The combination arm achieved 48.5% — nearly six times that of the placebo arm (8.4%).
• Pathological Complete Response (pCR): The combination arm reached 24.8% versus only 1.0% in the control arm, demonstrating overwhelming treatment depth.

II. Safety and Surgical Tolerability

Safety analysis showed that adding toripalimab did not significantly increase the incidence of serious adverse events, and the majority of patients were able to complete surgery as planned. This is critically important for Stage III patients seeking curative resection.

III. Why Is Neoadjuvant Immunotherapy Increasingly Important in Lung Cancer?

The core significance of neoadjuvant therapy is to "eliminate micrometastatic disease early." Japanese physicians applying perioperative regimens emphasize precise correlation of imaging and pathological findings. Medical Supporter has observed that Japan's top cancer centers are widely adopting these regimens to convert previously unresectable cases into curative surgical opportunities.

Medical Supporter: Your Expert for Lung Cancer Surgery and Immunotherapy Planning If you are in the treatment decision phase for Stage III lung cancer, seeking evaluation from Japanese specialists for a neoadjuvant regimen may improve your chances of long-term survival. Medical Supporter's team can connect you with Japanese medical institutions with extensive NEOTORCH protocol experience, providing the most professional cross-border support for your surgery and post-operative maintenance.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Lung cancer